(JYNT) The Joint - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US47973J1025
Stock: Chiropractic, Clinic, Franchise, Wellness
Total Rating 25
Risk 41
Buy Signal -0.38
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 47.4% |
| Relative Tail Risk | -14.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.26 |
| Alpha | -28.98 |
| Character TTM | |
|---|---|
| Beta | 0.853 |
| Beta Downside | 1.254 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.57% |
| CAGR/Max DD | -0.24 |
Description: JYNT The Joint January 01, 2026
The Joint Corp. (NASDAQ:JYNT) is a publicly-traded franchise operator of chiropractic clinics across the United States. Incorporated in 2010 and based in Scottsdale, Arizona, the company is classified under the Health Care Facilities sub-industry in the GICS taxonomy.
As of the most recent 10-K filing (FY 2023), The Joint reported approximately 250 franchised locations, generating $210 million in revenue with a year-over-year same-store sales growth of 8%. The franchise model yields an EBITDA margin of roughly 15%, reflecting the low-capital, high-leverage nature of the business. Key sector drivers include the aging U.S. population (projected to reach 73 million over 65 by 2030) and growing consumer preference for non-pharmaceutical pain-management solutions, both of which support demand for chiropractic services.
For a deeper, data-rich perspective on The Joint’s valuation dynamics, you might find ValueRay’s analytical dashboards worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -799.1k TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -5.94 > 1.0 |
| NWC/Revenue: 1824 % < 20% (prev 19.72%; Δ 1805 % < -1%) |
| CFO/TA 0.04 > 3% & CFO 3.07m > Net Income -799.1k |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.4m) vs 12m ago 1.72% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.94% > 50% (prev 107.5%; Δ -105.6% > 0%) |
| Interest Coverage Ratio: -0.54 > 6 (EBITDA TTM -1.43m / Interest Expense TTM -6.01m) |
Altman Z'' 0.41
| A: 0.38 (Total Current Assets 59.4m - Total Current Liabilities 33.0m) / Total Assets 69.4m |
| B: -0.37 (Retained Earnings -25.8m / Total Assets 69.4m) |
| C: -0.04 (EBIT TTM -3.26m / Avg Total Assets 74.5m) |
| D: -0.55 (Book Value of Equity -25.8m / Total Liabilities 46.7m) |
| Altman-Z'' Score: 0.41 = B |
Beneish M 1.00
| DSRI: 40.04 (Receivables 2.90m/4.30m, Revenue 1.44m/85.6m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.58 (AQ_t 0.08 / AQ_t-1 0.13) |
| SGI: 0.02 (Revenue 1.44m / 85.6m) |
| TATA: -0.06 (NI -799.1k - CFO 3.07m) / TA 69.4m) |
| Beneish M-Score: 28.09 (Cap -4..+1) = D |
What is the price of JYNT shares?
As of February 08, 2026, the stock is trading at USD 9.72 with a total of 36,846 shares traded.
Over the past week, the price has changed by -4.96%, over one month by +9.61%, over three months by +15.42% and over the past year by -15.15%.
Over the past week, the price has changed by -4.96%, over one month by +9.61%, over three months by +15.42% and over the past year by -15.15%.
Is JYNT a buy, sell or hold?
The Joint has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy JYNT.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the JYNT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.7 | 9.8% |
| Analysts Target Price | 10.7 | 9.8% |
| ValueRay Target Price | 9.4 | -3.6% |
JYNT Fundamental Data Overview February 07, 2026
P/E Forward = 12.6904
P/S = 2.6886
P/B = 6.4013
P/EG = -0.7
Revenue TTM = 1.44m USD
EBIT TTM = -3.26m USD
EBITDA TTM = -1.43m USD
Long Term Debt = 2.09m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 191.6k USD (from shortTermDebt, last quarter)
Debt = 2.09m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.6m USD (from netDebt column, last quarter)
Enterprise Value = 117.0m USD (145.7m + Debt 2.09m - CCE 30.7m)
Interest Coverage Ratio = -0.54 (Ebit TTM -3.26m / Interest Expense TTM -6.01m)
EV/FCF = 71.69x (Enterprise Value 117.0m / FCF TTM 1.63m)
FCF Yield = 1.39% (FCF TTM 1.63m / Enterprise Value 117.0m)
FCF Margin = 113.1% (FCF TTM 1.63m / Revenue TTM 1.44m)
Net Margin = -55.34% (Net Income TTM -799.1k / Revenue TTM 1.44m)
Gross Margin = unknown ((Revenue TTM 1.44m - Cost of Revenue TTM 11.6m) / Revenue TTM)
Tobins Q-Ratio = 1.69 (Enterprise Value 117.0m / Total Assets 69.4m)
Interest Expense / Debt = 175.5% (Interest Expense 3.67m / Debt 2.09m)
Taxrate = 3.44% (10.3k / 300.7k)
NOPAT = -3.15m (EBIT -3.26m * (1 - 3.44%)) [loss with tax shield]
Current Ratio = 1.80 (Total Current Assets 59.4m / Total Current Liabilities 33.0m)
Debt / Equity = 0.09 (Debt 2.09m / totalStockholderEquity, last quarter 22.7m)
Debt / EBITDA = 19.97 (negative EBITDA) (Net Debt -28.6m / EBITDA -1.43m)
Debt / FCF = -17.53 (Net Debt -28.6m / FCF TTM 1.63m)
Total Stockholder Equity = 21.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.07% (Net Income -799.1k / Total Assets 69.4m)
RoE = -3.70% (Net Income TTM -799.1k / Total Stockholder Equity 21.6m)
RoCE = -13.74% (EBIT -3.26m / Capital Employed (Equity 21.6m + L.T.Debt 2.09m))
RoIC = -15.03% (negative operating profit) (NOPAT -3.15m / Invested Capital 20.9m)
WACC = 8.93% (E(145.7m)/V(147.7m) * Re(9.06%) + (debt cost/tax rate unavailable))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.16%
[DCF Debug] Terminal Value 66.11% ; FCFF base≈3.62m ; Y1≈2.38m ; Y5≈1.08m
Fair Price DCF = 3.15 (EV 18.2m - Net Debt -28.6m = Equity 46.9m / Shares 14.9m; r=8.93% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -4.72 | EPS CAGR: 0.36% | SUE: -0.14 | # QB: 0
Revenue Correlation: -34.83 | Revenue CAGR: -12.53% | SUE: 0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.04 | Chg30d=-0.010 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.27 | Chg30d=-0.094 | Revisions Net=-1 | Growth EPS=+845.4% | Growth Revenue=+5.8%
P/S = 2.6886
P/B = 6.4013
P/EG = -0.7
Revenue TTM = 1.44m USD
EBIT TTM = -3.26m USD
EBITDA TTM = -1.43m USD
Long Term Debt = 2.09m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 191.6k USD (from shortTermDebt, last quarter)
Debt = 2.09m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.6m USD (from netDebt column, last quarter)
Enterprise Value = 117.0m USD (145.7m + Debt 2.09m - CCE 30.7m)
Interest Coverage Ratio = -0.54 (Ebit TTM -3.26m / Interest Expense TTM -6.01m)
EV/FCF = 71.69x (Enterprise Value 117.0m / FCF TTM 1.63m)
FCF Yield = 1.39% (FCF TTM 1.63m / Enterprise Value 117.0m)
FCF Margin = 113.1% (FCF TTM 1.63m / Revenue TTM 1.44m)
Net Margin = -55.34% (Net Income TTM -799.1k / Revenue TTM 1.44m)
Gross Margin = unknown ((Revenue TTM 1.44m - Cost of Revenue TTM 11.6m) / Revenue TTM)
Tobins Q-Ratio = 1.69 (Enterprise Value 117.0m / Total Assets 69.4m)
Interest Expense / Debt = 175.5% (Interest Expense 3.67m / Debt 2.09m)
Taxrate = 3.44% (10.3k / 300.7k)
NOPAT = -3.15m (EBIT -3.26m * (1 - 3.44%)) [loss with tax shield]
Current Ratio = 1.80 (Total Current Assets 59.4m / Total Current Liabilities 33.0m)
Debt / Equity = 0.09 (Debt 2.09m / totalStockholderEquity, last quarter 22.7m)
Debt / EBITDA = 19.97 (negative EBITDA) (Net Debt -28.6m / EBITDA -1.43m)
Debt / FCF = -17.53 (Net Debt -28.6m / FCF TTM 1.63m)
Total Stockholder Equity = 21.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.07% (Net Income -799.1k / Total Assets 69.4m)
RoE = -3.70% (Net Income TTM -799.1k / Total Stockholder Equity 21.6m)
RoCE = -13.74% (EBIT -3.26m / Capital Employed (Equity 21.6m + L.T.Debt 2.09m))
RoIC = -15.03% (negative operating profit) (NOPAT -3.15m / Invested Capital 20.9m)
WACC = 8.93% (E(145.7m)/V(147.7m) * Re(9.06%) + (debt cost/tax rate unavailable))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.16%
[DCF Debug] Terminal Value 66.11% ; FCFF base≈3.62m ; Y1≈2.38m ; Y5≈1.08m
Fair Price DCF = 3.15 (EV 18.2m - Net Debt -28.6m = Equity 46.9m / Shares 14.9m; r=8.93% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -4.72 | EPS CAGR: 0.36% | SUE: -0.14 | # QB: 0
Revenue Correlation: -34.83 | Revenue CAGR: -12.53% | SUE: 0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.04 | Chg30d=-0.010 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.27 | Chg30d=-0.094 | Revisions Net=-1 | Growth EPS=+845.4% | Growth Revenue=+5.8%